

MODERNA INC.

ISIN: US60770K1079 WKN: 60770K107 Asset Class: Stock

Company

2021/06/17 19:34:04

Price

202.35

USD

Difference



2.28%(4.51)



Contact Details

MODERNA, INC. Tel: 1-617-714-6500
 -- Fax: 617-583-1998
 200 Technology Square Web: <http://www.modernatx.com>
 02139 Cambridge E-mail: info@modernatx.com

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	6,297,879,000		1,128,804,000		1,563,006,000	
Common stock capital		40,000		34,000		33,000
Fixed assets	1,038,871,000		460,618,000		399,143,000	
Equity capital of a company		2,561,375,000		1,174,810,000		1,530,241,000
Cash and cash equivalents	2,624,882,000		236,908,000		658,959,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		4,388,808,000		143,115,000		222,803,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		386,567,000		271,497,000		209,105,000
Different income		-		-		-
Other liabilities		179,272,000		139,133,000		175,616,000
Total assets	7,336,750,000	7,336,750,000	1,589,422,000	1,589,422,000	1,962,149,000	1,962,149,000

Balance notes

	2020	2019	2018
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	1,300	830	760
Equity ratio	34.91%	73.91%	77.99%
Debt-equity ratio	186.44%	35.29%	28.22%

Others

	2020	2019	2018
Tax Expense Rate	-0.34%	0.14%	12.56%

MODERNA INC.

ISIN: US60770K1079 WKN: 60770K107 Asset Class: Stock

Income statement

	2020	2019	2018
Turnover	803,395,000	60,209,000	135,068,000
Net income	-747,064,000	-514,021,000	-388,861,000
EBIT	-626,533,084	-451,027,713	-382,792,769
Operating income before taxes	-744,513,000	-514,716,000	-440,008,000
Cash Flow	2,015,179,000	-470,644,000	-330,865,000
Net interest income	14,829,000	31,918,000	23,927,000
Research and development expenses	1,339,088,000	465,288,000	509,682,000
Income taxes	2,551,000	-695,000	-55,274,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	509,909	59,854	146,638

Board of Directors

Members of Management Board

Noubar Afeyan	Chairman of Board of Directors
Elizabeth Nabel	Member of Board of Directors
Francois Nader	Member of Board of Directors
Robert Langer	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Elizabeth Tallett	Member of Board of Directors
Paul Sagan	Member of Board of Directors
Stephen Berenson	Member of Board of Directors
Stéphane Bancel	Chairman of Managing Board
Charbel Haber	Member of Executive Committee
Corinne Le Goff	Member of Executive Committee
José Vega	Member of Executive Committee
Melanie Ivarsson	Member of Executive Committee
Stephen Hoge	Member of Executive Committee
Tal Zaks	Member of Executive Committee
David Meline	Member of Executive Committee
Jacqueline Miller	Member of Executive Committee
Jennifer Lee	Member of Executive Committee
John Lepore	Member of Executive Committee
Juan Andres	Member of Executive Committee